Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
NewLink Genetics updates financial and clinical guidance
View HTML
Toggle Summary NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
AMES, Iowa , Dec. 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) announced today that the company will present at the 36 th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 , at 11:00am PT / 2:00pm ET in San Francisco , CA.  A live webcast of the
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conference
AMES, Iowa , Nov. 27, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) will participate in the Global Mizuho Investor Conference on Tuesday, December 5 th , in New York City.  The format of the conference is one-on-one meetings with investors only.  About NewLink Genetics
View HTML
Toggle Summary NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
AMES, Iowa , Nov. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the presentation of data from a Phase 1 study of indoximod, in combination with radiation, for children with progressive brain tumors.  These data were presented at the Society for
View HTML
Toggle Summary NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
AMES, Iowa , Nov. 14, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Eugene P. Kennedy , M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all clinical development, medical affairs and related functions. Dr.
View HTML
Toggle Summary NewLink Genetics to Participate in November Investor Conferences
AMES, Iowa , Nov. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) will participate in the following investor conferences this week: Stifel 2017 Healthcare Conference on Tuesday, November 14 th , at 5:00pm ET in New York City Jefferies 2017 London Healthcare Conference
View HTML
Toggle Summary NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program
- Management to Host Conference Call Today at 8:30 a.m. ET
View HTML
Toggle Summary NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 
AMES, Iowa , Oct. 30, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that indoximod, its leading drug development candidate, was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Stage IIb-IV
View HTML
Toggle Summary NewLink Genetics to Host Its Third Quarter 2017 Financial Results Conference Call on November 2, 2017
AMES, Iowa , Oct. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today announced that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and
View HTML
Toggle Summary NewLink Genetics Prices Public Offering of Common Stock
AMES, Iowa , Oct. 03, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (" NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $10.25 per
View HTML